Rob C. Van Wijk

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Predicting tuberculosis relapse based on 28-day CFU, RS ratio, and/or drug contribution for novel regimens in the relapsing mouse model.

Predicting tuberculosis relapse based on 28-day CFU, RS ratio, and/or drug contribution for novel regimens in the relapsing mouse model.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology.

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology.

Journal: Clinical pharmacology and therapeutics

Published: May 29, 2026

Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis.

Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis.

Journal: Open forum infectious diseases

Published: February 17, 2026

Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach.

Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: November 27, 2025

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network.

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network.

Journal: Clinical pharmacology and therapeutics

Published: November 26, 2025

Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.

Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.

Journal: Science translational medicine

Published: February 05, 2025

Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models.

Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models.

Journal: The Journal of infectious diseases

Published: October 29, 2024

Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data.

Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data.

Journal: iScience

Published: August 29, 2024

Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.

Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.

Journal: Vaccines

Published: January 23, 2024

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.

Journal: bioRxiv : the preprint server for biology

Published: January 30, 2023

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.

Journal: The European respiratory journal

Published: January 25, 2023

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development.

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development.

Journal: Frontiers in pharmacology

Published: January 23, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026